Publicacions en què col·labora amb Valentí Fuster (32)

2023

  1. Magnetic resonance imaging reference values for cardiac morphology, function and tissue composition in adolescents

    eClinicalMedicine, Vol. 57

2022

  1. Rationale and design of the pragmatic clinical trial tREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT)

    European heart journal. Cardiovascular pharmacotherapy, Vol. 8, Núm. 3, pp. 291-301

2021

  1. A novel circulating microRNA for the detection of acute myocarditis

    New England Journal of Medicine, Vol. 384, Núm. 21, pp. 2014-2027

  2. Clinical Validation of a 3-Dimensional Ultrafast Cardiac Magnetic Resonance Protocol Including Single Breath-Hold 3-Dimensional Sequences

    JACC: Cardiovascular Imaging, Vol. 14, Núm. 9, pp. 1742-1754

  3. Coexistence of transmural and lateral wavefront progression of myocardial infarction in the human heart

    Revista Espanola de Cardiologia, Vol. 74, Núm. 10, pp. 870-877

  4. Intravenous metoprolol during ongoing STEMI ameliorates markers of ischemic injury: a METOCARD-CNIC trial electrocardiographic study

    Basic Research in Cardiology, Vol. 116, Núm. 1

  5. Remote ischaemic preconditioning ameliorates anthracycline-induced cardiotoxicity and preserves mitochondrial integrity

    Cardiovascular research, Vol. 117, Núm. 4, pp. 1132-1143

2020

  1. Beta-blocker effect on ST-segment: A prespecified analysis of the EARLY-BAMI randomised trial

    Open Heart, Vol. 7, Núm. 2

  2. Five-Year Outcomes and Prognostic Value of Feature-Tracking Cardiovascular Magnetic Resonance in Patients Receiving Early Prereperfusion Metoprolol in Acute Myocardial Infarction

    American Journal of Cardiology, Vol. 133, pp. 39-47

  3. Left ventricular functional recovery of infarcted and remote myocardium after ST-segment elevation myocardial infarction (METOCARD-CNIC randomized clinical trial substudy)

    Journal of Cardiovascular Magnetic Resonance, Vol. 22, Núm. 1

  4. Metoprolol blunts the time-dependent progression of infarct size

    Basic Research in Cardiology, Vol. 115, Núm. 5

2019

  1. Effect of Early Metoprolol During ST-Segment Elevation Myocardial Infarction on Left Ventricular Strain: Feature-Tracking Cardiovascular Magnetic Resonance Substudy From the METOCARD-CNIC Trial

    JACC: Cardiovascular Imaging, Vol. 12, Núm. 7, pp. 1188-1198

  2. Serial Magnetic Resonance Imaging to Identify Early Stages of Anthracycline-Induced Cardiotoxicity

    Journal of the American College of Cardiology, Vol. 73, Núm. 7, pp. 779-791

2017

  1. Effect of Ischemia Duration and Protective Interventions on the Temporal Dynamics of Tissue Composition after Myocardial Infarction

    Circulation Research, Vol. 121, Núm. 4, pp. 439-450

  2. El volumen extracelular no se asocia a arritmias malignas en miocardiopatía hipertrófica de alto riesgo

    Revista Espanola de Cardiologia, Vol. 70, Núm. 11, pp. 933-940

  3. Impacto del territorio miocárdico infartado en la cuantificación del área en riesgo mediante cardiorresonancia magnética

    Revista Espanola de Cardiologia, Vol. 70, Núm. 5, pp. 323-330

  4. Neutrophil stunning by metoprolol reduces infarct size

    Nature Communications, Vol. 8

  5. Nutritional preconditioning by marine omega-3 fatty acids in patients with ST-segment elevation myocardial infarction: A METOCARD-CNIC trial substudy

    International Journal of Cardiology, Vol. 228, pp. 828-833

2016

  1. Beta-3 adrenergic agonists reduce pulmonary vascular resistance and improve right ventricular performance in a porcine model of chronic pulmonary hypertension

    Basic Research in Cardiology, Vol. 111, Núm. 4

  2. Early Intravenous Beta-Blockers in Patients With ST-Segment Elevation Myocardial Infarction Before Primary Percutaneous Coronary Intervention

    Journal of the American College of Cardiology, Vol. 67, Núm. 23, pp. 2705-2715